Bimekizumab (Bimzelx)

What is bimekizumab?

Bimekizumab (Bimzelx) is an injectable biologic medication used in dermatology for moderate-to-severe plaque psoriasis. It is a newer IL-17 pathway treatment and is also relevant in dermatology because it is approved for hidradenitis suppurativa.

How does bimekizumab work?

Bimekizumab blocks both interleukin-17A and interleukin-17F, two inflammatory signals that play a major role in psoriasis. By reducing activity in this pathway, it can help decrease skin inflammation, scaling, and plaque formation.

Blocking both IL-17A and IL-17F is one of the features that makes bimekizumab distinct from some other biologics in the same general pathway.

What are possible side effects of bimekizumab?

Possible side effects can include:

  • Upper respiratory symptoms

  • Oral yeast infection or thrush

  • Injection site reactions

  • Headache in some patients

As with other biologic medications, infection screening, vaccination review, and overall treatment risks should be discussed with the prescribing clinician. Patients with a history of recurrent yeast infections or certain bowel symptoms may need a more individualized discussion.

How is bimekizumab used?

Bimekizumab is given by injection on a schedule directed by your provider. Some patients may be able to self-inject after training. The medication is stored in the refrigerator.

Because it is a psoriasis biologic, many patients and clinicians may compare it with other IL-17 or IL-23 treatments when deciding which option is the best fit. The choice often depends on psoriasis severity, joint symptoms, past biologic response, and insurance coverage.

THIS CONTENT IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES AND MAY NOT BE COMPREHENSIVE. IT DOES NOT CONSTITUTE MEDICAL ADVICE. PLEASE REFER TO OUR TERMS OF USE FOR FURTHER DETAILS. ALWAYS CONSULT WITH YOUR HEALTHCARE PROVIDER BEFORE MAKING ANY MEDICAL DECISIONS.